News

OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in personalized ophthalmic care.

A study suggests that small hyperreflective retinal foci (HRF) on OCT images, linked to activated microglial cells, could serve as a valuable marker for monitoring neuroretinal inflammation and progression in age-related macular degeneration.

Early results suggest participant diversity and novel measures will enable new, artificial intelligence-driven insights. As the study evolves, it could lead to significant advancements in understanding how environmental exposures contribute not only to diabetes but also to its complications, including those affecting eye health, such as diabetic retinopathy.

Arshad Khanani, MD, MA, FASRS, presented positive data from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314.

Research explores innovative physiotherapeutic approaches to managing myopia progression, showing promising results in slowing its advancement over two years.

A study found that a simplified artificial circuit, modeled after the brain's neuronal system, can predict network activity and provide insights into how the brain manages short-term memory, with potential implications for novel treatments of eye movement disorders.

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.

Uveitic relapses primarily manifest as anterior uveitis, the authors said

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

A study by a team of Chinese researchers highlights the potential of optical coherence tomography angiography (OCTA) in detecting retinal microvascular damage in renal hypertension patients. OCTA identifies reduced vascular density in key retinal regions, offering a noninvasive tool for early diagnosis and systemic disease management.

Today’s technology proves faster, better, cheaper.

Connell’s appointment was effective immediately after the Annual General Meeting of the Company on November 15, 2024.

At the ESCRS meeting, Sir Harold Ridley’s legacy was put on display in a pop-up museum installation

Dosing in the first phase of the phase 1/2 OCU410ST GARDian trial for Stargardt disease is complete.

Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are exposed to low humidity, strong ultraviolet rays, cold and dry weather, and low pressure and hypoxia

The NHS is expanding the use of optical coherence tomography to enhance diabetic eye care, aiming to improve early detection of diabetic retinopathy and reduce the backlog of hospital appointments.

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.

The program aims to expand access and affordability for Harrow's ophthalmic pharmaceutical products through targeted price reductions and a strategic partnership with GoodRx.

Research is needed to establish the best diagnostic and management strategies for increasingly common condition

This Week in Ophthalmology is a weekly video series highlighting the latest news and articles featured on the Ophthalmology Times website.

The CHMP has recommended FYB203 for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices.

Cerebral/cortical visual impairment (CVI) is a leading cause of childhood blindness, caused by brain damage to visual pathways. Researchers are refining its definition and diagnostic methods to improve early detection and treatment, enhancing outcomes for affected children.

Research needed to establish best diagnostic and management strategies for increasingly common condition.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.

Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.